Novavax, Inc.

NASDAQ:NVAX

Biotechnology

Healthcare
$7.96 -1.84%

-$0.18 today

Market cap
$1.31B
Beta
2.41
P/E (TTM)
-17.3
EPS (TTM)
-$0.54
52W Low $6.13High $11.97

Volume 4.24M

Average 4.58M

NVAX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Novavax, Inc.NASDAQ: NVAX

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA turns negative

Q1 FY2026 EBITDA was -$543K, compared with $533.91M a year earlier. Trailing-twelve-month EBITDA was -$42.13M.

Context

  • EBITDA amounted to 43.8% of revenue in FY2025, up 28.0 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 5 analysts of $37.37M (-92.4%) for the fiscal year ending Dec 2026, a slowdown from the +555.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$543K-101.9% QoQ
Last fiscal yearDec 2025
$492.33M+555.7% YoY
LTMMar 2026
-$42.13M-107.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.1%-144.7%-44.6 pp
1 year+555.7%-92.4%-648.1 pp
3-year CAGR—-64.4%—
5-year CAGR-9.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
492.33M USD
Year-over-year change
+555.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How NVAX compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -107.6% is the 5th highest of 8, against a peer median of -3.7%.
  • EBITDA amounts to 7.1% of revenue for NVAX, versus a peer median of 57.7%.
NVAX Competitors
EBITDA for NVAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EBSEmergent BioSolutions Inc.LTM Mar 2026$154.5M USD+28.1%+148.3%22.8%
NVAXNovavax, Inc.LTM Mar 2026-$42.13M USD-107.6%—7.1%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$67.53M USD-3.7%—148.9%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$81.94M USD+12.2%——
VALNValneva SELTM Mar 2026-€90.14M EUR-119.6%—57.7%
BNTXBioNTech SELTM Jun 2026-€941.06M EUR-2167.6%—35.6%
PCVXVaxcyte, Inc.LTM Jun 2026-$1.05B USD-116.2%——
MRNAModerna, Inc.LTM Sep 2026-$2.46B USD+16.4%—97.2%
Peer median (excluding NVAX) —-3.7%+148.3%57.7%

Competitors are the stored peer set for NVAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue197.58M1.6B556.38M682.16M1.12B
Cost of Revenue0902.64M343.77M202.74M71.14M
Gross Profit197.58M696.31M212.61M479.42M1.05B
Gross Margin100.0%43.5%38.2%70.3%93.7%
Research & Development2.53B1.24B737.5M391.17M336.82M
Selling, General & Admin298.36M488.69M468.95M337.19M150.35M
Operating Expenses1.88B1.34B779.13M728.35M489.07M
Depreciation & Amortization12.66M29.05M41.23M48.5M27.61M
EBITDA(1.68B)(604.71M)(487.39M)(108.04M)492.33M
EBITDA Margin-850.7%-37.8%-87.6%-15.8%43.8%
Operating Income(1.69B)(644.74M)(566.51M)(248.93M)563.27M
Operating Margin-853.6%-40.3%-101.8%-36.5%50.1%
Interest Income00000
Interest Expense21.13M19.88M14.42M20.08M22.55M
Other Income / Expenses(27.96M)(8.91M)23.48M72.32M(121.1M)
Income Before Tax(1.71B)(653.65M)(543.03M)(176.62M)442.17M
Pre-Tax Margin-867.8%-40.9%-97.6%-25.9%39.4%
Income Tax Expense29.22M4.29M2.03M10.88M1.87M
Net Income(1.74B)(657.94M)(545.06M)(187.5M)440.3M
Net Margin-882.5%-41.1%-98.0%-27.5%39.2%
EPS (Basic)(23.44)(8.42)(5.41)(1.23)2.72
EPS (Diluted)(23.44)(8.42)(5.41)(1.23)2.54
Weighted Avg Shares74.4M78.18M100.77M152.19M161.99M
Weighted Avg Shares (Diluted)74.4M78.18M100.77M152.19M173.1M

Novavax, Inc.

NASDAQ:NVAX

Intrinsic Alpha fair value

Locked

Current Price

$7.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.